Radiologisches Monitoring bei Immuntherapie des Nierenzellkarzinoms

Abstract

The Response Evaluation Criteria in Solid Tumours (RECIST 1.1) currently represent the most widely established evaluation criteria for standardised therapy monitoring in solid tumours treated with traditional cytostatic and cytotoxic tumour therapies. The increasing use of immune checkpoint inhibitors in the therapy of metastatic renal cell carcinoma poses special challenges for radiological therapy monitoring due to the presence of atypical response patterns and immunotherapy-specific side-effects. Adapted criteria such as immune RECIST (iRECIST) can help in the follow-up assessment of renal cell carcinoma to detect atypical courses of disease under immune checkpoint inhibitor therapy both within and outside of clinical trials.